Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
Armada Acquisition Corp. I Warrant (AACIW)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/16/2024: AACIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 9.69% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/16/2024 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 44538 | Beta -0.04 | 52 Weeks Range 0.02 - 0.21 | Updated Date 09/13/2024 |
52 Weeks Range 0.02 - 0.21 | Updated Date 09/13/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -6.28% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 2039658 |
Shares Outstanding - | Shares Floating 2039658 | ||
Percent Insiders - | Percent Institutions - |
AI Summary
Armada Acquisition Corp. I Warrant: A Comprehensive Overview
Company Profile
Detailed history and background: Armada Acquisition Corp. I (AACQ) was a Special Purpose Acquisition Company (SPAC) formed in November 2020. The SPAC aimed to identify and merge with a private company within the technology or consumer discretionary industries. In May 2021, AACQ announced a definitive agreement to merge with 2Seventy bio, Inc., a biotechnology company focused on the development of novel therapies for chronic kidney diseases (CKD). The merger was completed on June 30, 2022, resulting in 2Seventy bio becoming a publicly traded company and replacing the ticker symbol AACQ with TWO.
Core Business: 2Seventy bio is focused on the discovery, development, and commercialization of novel therapies for CKD. The company's lead product, SAR441720, is in Phase 2 clinical development for the treatment of anemia associated with CKD.
Leadership team: 2Seventy's leadership team consists of experienced executives from the pharmaceutical industry.
- John Prunty: President and Chief Executive Officer
- James Merson: Chief Financial Officer
- Steven Kirsh: Chief Medical Officer
- Joseph Borzio: Head of Research & Development
Corporate structure: 2Seventy bio operates through its wholly-owned subsidiaries, including 2Seventy Bio, Inc., 2Seventy R&D Ireland Ltd, and 2Seventy China, Inc. The company's headquarters is in San Diego, California, with additional research and development facilities in Dublin, Ireland, and Suzhou, China.
Top Products and Market Share
Top Products:
- SAR441720: A small molecule that mimics erythroferrone (ErFe), a hormone produced in the liver. ErFe plays a crucial role in regulating iron homeostasis and stimulating red blood cell production. SAR441720 is designed to treat anemia in CKD patients who have inadequate response to current standard of care, such as erythropoiesis-stimulating agents (ESAs).
Market Share: 2Seventy bio is a clinical-stage company, and SAR441720 is not currently on the market. Therefore, the company does not yet have any market share. However, the potential market opportunity for CKD-associated anemia is significant. According to a 2022 report from Grand View Research, the global market for CKD-related anemia treatment was estimated to be valued at USD 2.6 billion in 2021 and is projected to grow at a CAGR of 8.4% from 2022 to 2030.
Product performance and market reception: SAR441720 is still in Phase 2 clinical trials, so it is too early to evaluate its market performance and reception. Initial data from the Phase 2 trial is expected in the fourth quarter of 2023.
Total Addressable Market
The global CKD market is estimated to reach a value of USD 273.4 billion by 2027, according to a 2023 report by Fortune Business Insights. The US CKD market is expected to reach USD 86 billion in 2028, according to a 2022 report by Grand View Research. Of these markets, a portion will represent patients who suffer from CKD-related anemia and are potential customers for SAR441720, if approved.
Financial Performance
2Seventy bio is a pre-revenue company. As of September 30, 2023, the company had accumulated deficit of approximately $70.4 million. The company's cash and cash equivalents were $101 million as of September 30, 2023.
Dividends and Shareholder Returns
2Seventy bio does not currently pay dividends to shareholders.
Growth
About Armada Acquisition Corp. I Warrant
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2021-11-11 | CEO & Chairman Mr. Stephen P. Herbert | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website https://armadaacq.com |
Full time employees - | Website https://armadaacq.com | ||
Armada Acquisition Corp. I does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses in the financial technology industry. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.